PubMedCrossRef 15. Turashvili G, Bouchal J, Burkadze G, Kolar Z: Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 2006, 73:213–223.PubMedCrossRef 16. Fodde R, Brabletz T: Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007, 19:150–158.PubMedCrossRef 17.
Shiina H, Igawa M, Breault J, Ribeiro-Filho L, Pookot D, Urakami S, Terashima M, Deguchi M, Yamanaka M, Shirai M, Kaneuchi M, Kane CJ, Dahiya R: The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. Clin Cancer Res 2003, 9:2121–2132.PubMed 18. He TC, www.selleckchem.com/products/gs-9973.html Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509–1512.PubMedCrossRef 19. Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422–426.PubMedCrossRef 20. Kawano Y, Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003, 116:2627–34.PubMedCrossRef 21. Hu YA, Gu X, Liu J, Yang Y, Yan Y, Zhao C: Expression pattern of Wnt inhibitor factor 1(Wif1) during the development in mouse CNS. Gene Expr
Patterns 2008, AZD6738 order 8:515–522.PubMedCrossRef 22. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415–428.PubMedCrossRef 23. cAMP Herman JG, Baylin SB: Gene silencing in cancer in 10058-F4 nmr association with promoter hypermethylation. N Engl J Med 2003, 349:2042–2054.PubMedCrossRef 24. Vladimirova V, Mikeska T, Waha A, Soerensen N, Xu J, Reynolds PC, Pietsch T: Aberrant methylation and reduced expression of LHX9 in malignant astrocytomas of childhood. Neoplasia 2009, 11:700–711.PubMed 25. Blanc
JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, Lapierre F, Larsen CJ, Karayan-Tapon L: Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004, 68:275–283.PubMedCrossRef 26. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP: Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer 1997, 75:2–8.PubMedCrossRef 27. Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamguney T, Baumber R, Parsons R, Lamborn KR, Berger MS, Wrensch MR, Haas-Kogan DA, Stokoe D: Methylation of the PTEN promoter defines low-grade astrocytomas and secondary glioblastoma. Neuro Oncol 2007, 9:271–279.PubMedCrossRef 28. Wemmert S, Bettscheider M, Alt S, Ketter R, Kammers K, Feiden W, Steudel WI, Rahnenfuhrer J, Urbschat S: p15 promoter methylation – a novel prognostic marker in glioblastoma patients. Int J Oncol 2009, 34:1743–1748.PubMed 29.
Related posts:
- PubMedCrossRef 3 Portela A, Esteller M: Epigenetic modifications
- Mol Cell Biochem 2006, 286: 67–76 PubMedCrossRef 13 Fong WG, Lis
- J Cell Physiol 2006, 207:520–529 PubMedCrossRef
8 Caloge - Stem Cells 2008,26(6):1414–1424 PubMedCrossRef 12 Chung LW, Base
- Cancer Res 2007, 67:4725–4731 PubMedCrossRef 28 Wente MN, Gaida